Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naldemedine - Shionogi

Drug Profile

Naldemedine - Shionogi

Alternative Names: Rizmoic; S-297995; Symproic

Latest Information Update: 14 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Purdue Pharma; Shionogi
  • Class Antiemetics; Laxatives; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II Postoperative ileus

Most Recent Events

  • 04 Jan 2021 Shionogi terminates a phase-II clinical trial in Postoperative ileus (In the elderly, In adults) due to slow patient enrollments, in USA (PO) (NCT04355169)
  • 01 Sep 2020 Phase-II clinical trials in Postoperative ileus (In the elderly, In adults) in USA (PO) (NCT04355169)
  • 23 Apr 2020 Shionogi plans a phase II trial for Postoperative ileus in USA (In adults, In the elderly) (PO), in May 2020 (NCT04355169 )
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top